These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20447065)

  • 21. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN; Comninos AN; Clarke H; Donaldson M; Meeran K; Dhillo WS
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different relationships between the first 2 years on growth hormone treatment and the d3-growth hormone receptor polymorphism in short small-for-gestational-age (SGA) children.
    Dörr HG; Bettendorf M; Hauffa BP; Mehls O; Rohrer T; Stahnke N; Pfäffle R; Ranke MB;
    Clin Endocrinol (Oxf); 2011 Nov; 75(5):656-60. PubMed ID: 21623854
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short stature and decreased insulin-like growth factor I (IGF-I)/growth hormone (GH)-ratio in an adult GH-deficient patient pointing to additional partial GH insensitivity due to a R179C mutation of the growth hormone receptor.
    Meyer S; Ipek M; Keth A; Minnemann T; von Mach MA; Weise A; Ittner JR; Nawroth PP; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Kann PH; ;
    Growth Horm IGF Res; 2007 Aug; 17(4):307-14. PubMed ID: 17462934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum leptin levels and GHR-d3/fl gene polymorphism in acromegalic patients with thyroid nodules.
    Topsakal S; Akin F; Turgut S; Yerlikaya E; Yaylali GF
    Adv Clin Exp Med; 2017; 26(2):281-286. PubMed ID: 28791847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormonal diagnosis of GH hypersecretory states.
    Grottoli S; Gasco V; Ragazzoni F; Ghigo E
    J Endocrinol Invest; 2003; 26(10 Suppl):27-35. PubMed ID: 15497657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth hormone (GH) dose, but not exon 3-deleted/full-length GH receptor polymorphism genotypes, influences growth response to two-year GH Therapy in Short Small-for-Gestational-Age Children.
    Carrascosa A; Audí L; Esteban C; Fernández-Cancio M; Andaluz P; Gussinyé M; Clemente M; Yeste D; Albisu MA
    J Clin Endocrinol Metab; 2008 Jan; 93(1):147-53. PubMed ID: 17925340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?
    Damjanovic SS; Neskovic AN; Petakov MS; Popovic V; Macut D; Vukojevic P; Joksimovic MM
    Clin Endocrinol (Oxf); 2005 Apr; 62(4):410-7. PubMed ID: 15807870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GH receptor d3 polymorphism in Dutch patients with MPHD and IGHD born small or appropriate for gestational age.
    de Graaff LC; Meyer S; Els C; Hokken-Koelega AC
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):930-4. PubMed ID: 18031312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between weight-based and IGF-I-based growth hormone (GH) dosing in the treatment of children with GH deficiency and influence of exon 3 deleted GH receptor variant.
    Marchisotti FG; Jorge AA; Montenegro LR; Berger K; de Carvalho LR; Mendonca BB; Arnhold IJ
    Growth Horm IGF Res; 2009 Apr; 19(2):179-86. PubMed ID: 19036620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register.
    Petersenn S; Buchfelder M; Gerbert B; Franz H; Quabbe HJ; Schulte HM; Grussendorf M; Reincke M;
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):400-5. PubMed ID: 19226273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The exon 3 deleted growth hormone receptor gene is associated with small birth size and early pubertal onset in healthy boys.
    Sørensen K; Aksglaede L; Petersen JH; Leffers H; Juul A
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2819-26. PubMed ID: 20382688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over two years in prepubertal short children born at term with adequate weight and length for gestational age.
    Carrascosa A; Audí L; Fernández-Cancio M; Esteban C; Andaluz P; Vilaró E; Clemente M; Yeste D; Albisu MA; Gussinyé M
    J Clin Endocrinol Metab; 2008 Mar; 93(3):764-70. PubMed ID: 18160465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of the exon 3-deleted/full-length growth hormone (GH) receptor polymorphism on the response to GH replacement therapy in adults with severe GH deficiency.
    Barbosa EJ; Palming J; Glad CA; Filipsson H; Koranyi J; Bengtsson BA; Carlsson LM; Boguszewski CL; Johannsson G
    J Clin Endocrinol Metab; 2009 Feb; 94(2):639-44. PubMed ID: 19050057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. d3-GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults.
    Moyes VJ; Walker DM; Owusu-Antwi S; Maher KT; Metherell L; Akker SA; Monson JP; Clark AJ; Drake WM
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):807-13. PubMed ID: 20039885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discordant nadir GH after oral glucose and IGF-I levels on treated acromegaly: refining the biochemical markers of mild disease activity.
    Elias PC; Lugao HB; Pereira MC; Machado HR; Castro Md; Moreira AC
    Horm Metab Res; 2010 Jan; 42(1):50-5. PubMed ID: 19798623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GH receptor isoforms and skeletal fragility in acromegaly.
    Mormando M; Nasto LA; Bianchi A; Mazziotti G; Giampietro A; Pola E; Pontecorvi A; Giustina A; De Marinis L
    Eur J Endocrinol; 2014 Aug; 171(2):237-45. PubMed ID: 24866575
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of serum components of the GH-IGFs-IGFBPs system with GHR-exon 3 polymorphism in normal and idiopathic short stature children.
    Ballerini MG; Domené HM; Scaglia P; Martínez A; Keselman A; Jasper HG; Ropelato MG
    Growth Horm IGF Res; 2013 Dec; 23(6):229-36. PubMed ID: 23999134
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism.
    Tauber M; Ester W; Auriol F; Molinas C; Fauvel J; Caliebe J; Nugent T; Fryklund L; Ranke MB; Savage MO; Clark AJ; Johnston LB; Hokken-Koelega AC;
    Clin Endocrinol (Oxf); 2007 Sep; 67(3):457-61. PubMed ID: 17555507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low serum IGF-I/GH ratio is associated with abnormal glucose tolerance in acromegaly.
    Fukuoka H; Takahashi Y; Iida K; Kudo T; Nishizawa H; Imanaka M; Takeno R; Iguchi G; Takahashi K; Okimura Y; Kaji H; Chihara K
    Horm Res; 2008; 69(3):165-71. PubMed ID: 18219220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.